BOC-4-硝基-苯丙氨酸乙酯 | 67630-00-6

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苯丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: BOC-4-硝基-苯丙氨酸乙酯
• 英文名称: N-(tert-butyloxycarbonyl)-4-nitro-L-phenylalanine ethyl ester
• 英文别名: N-tert-butoxycarbonyl-L-4-nitrophenylalanine ethyl ester；Boc-Phe(NO2)-OEt；N-tert-butoxycarbonyl-4-nitro-L-phenylalanine ethyl ester；N-t-butoxycarbonyl-DL-4-nitrophenylalanine ethyl ester；N-Boc-4-nitro-L-phenylalanine ethyl ester；Boc-Phe(4-NO2)-OEt；(S)-ethyl 2-(tert-butoxycarbonylamino)-3-(4-nitrophenyl)propanoate；ethyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-nitrophenyl)propanoate
• CAS: 67630-00-6
• 化学式: C₁₆H₂₂N₂O₆
• 分子量: 338.36
• InChiKey: KVEDDVRFINSSND-ZDUSSCGKSA-N

物化性质

• 沸点：
  481.9±40.0 °C(Predicted)
• 密度：
  1.198±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  BOC-4-硝基-苯丙氨酸乙酯 在 palladium on activated charcoal 氢气 、 ammonium formate 作用下， 以 甲醇 、 水 、 溶剂黄146 为溶剂， 反应 25.0h， 生成 N-boc-L-3-(4-bis(hydroxyethyl)aminophenyl)alanine ethyl ester
  参考文献：
  名称：

  Modulation of Melphalan Resistance in Glioma Cells with a Peripheral Benzodiazepine Receptor Ligand−Melphalan Conjugate

  摘要：

  Peripheral benzodiazepine receptors (PBRs) are located on the outer membrane of mitochondria, and their density is increased in brain tumors. Thus, they may serve as a unique intracellular and selective target for antineoplastic agents. A PBR ligand-melphalan conjugate (PBR-MEL) was synthesized and evaluated for cytotoxicity and affinity for PBRs. PBR-MEL (9) (i.e., 670 amu) was synthesized by coupling of two key intermediates: 4-[bis(2-chloroethyl)amino]-L-phenylalanine ethyl ester trifluoroacetate (6) and 1-(3'-carboxylpropyl)-7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one (8). On the basis of receptor-binding displacement assays in rat brain and glioma cells, 9 had appreciable binding affinity and displaced a prototypical PBR ligand, Ro 5-4864, with IC50 values between 289 and 390 nM. 9 displayed differential cytotoxicity to a variety of rat and human brain tumor cell lines. In some of the cell lines tested including rat and human melphalan-resistant cell lines, 9 demonstrated appreciable cytotoxicity with IC50 values in the micromolar range, lower than that of melphalan alone. The enhanced activity of 9 may reflect increased membrane permeability, increased intracellular retention, or modulation of melphalan's mechanisms of resistance. The combined data support additional studies to determine how 9 may modulate melphalan resistance, its mechanisms of action, and if target selectivity can be achieved in in vivo glioma models.

  DOI：

  10.1021/jm960592p
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 三乙胺 、 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 0.17h， 以100%的产率得到BOC-4-硝基-苯丙氨酸乙酯
  参考文献：
  名称：

  WO2006/115918

  摘要：

  公开号：

文献信息

• N-acylamino acid amide compounds and intermediates for preparation thereof
  申请人：Ube Industries, Ltd.

  公开号：US06265418B1

  公开（公告）日：2001-07-24

  The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.

  本发明公开了以下公式（I）所表示的化合物： 其中A代表以下公式（a-1）或以下公式（a-2）： B代表以下公式（b）： （其中符号如规范中所定义）或其药学上可接受的盐，以及用于制备其的中间体，具有优异的血小板聚集抑制活性和其他性质，并且可用作与纤维蛋白原受体、血栓形成、梗塞等疾病相关的预防或治疗剂。
• [EN] VLA-4 ANTAGONISTS<br/>[FR] ANTAGONISTES DE VLA-4
  申请人：MERCK & CO INC

  公开号：WO2005087760A1

  公开（公告）日：2005-09-22

  Compounds of Formula I are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn’s disease, multiple sclerosis, asthma, and rheumatoid arthritis.

  公式I的化合物是VLA-4的拮抗剂，因此在抑制或预防细胞粘附和细胞粘附介导的病理过程中非常有用。这些化合物可以制成药物组合物，并适用于治疗炎症性肠病，包括溃疡性结肠炎和克罗恩病，多发性硬化症，哮喘和类风湿性关节炎。
• Studies on analgesic oligopeptides. II. Structure-activity relationship among thirty analogs of a cyclic dipeptide, cyclo(-Tyr-Arg-)
  作者：YUSUKE SASAKI、YASUYUKI AKUTSU、MICHIKO MATSUI、KENJI SUZUKI、SHINOBU SAKURADA、TAKUMI SATO、KENSUKE KISARA

  DOI：10.1248/cpb.30.4435

  日期：——

  Thirty diketopiperazines were synthesized as analogs of cyclo (-Tyr-Arg-). The analgesic activities of these analogs were evaluated after intracerebral administration in mice. In the cyclo (-X-Arg-) series of analogs, cyclo [-Tyr (Et)-Arg-] showed the most potent activity. In the cyclo (-Tyr-Y-) series of analogs, the activity decreased in the order Y=homoarginine, p-guanidinophenylalanine, 2-amino-4-guanidinobutyric acid, Lys, Orn, His, α, γ-diaminobutyric acid and Pro. Among the analogs synthesized, cyclo-[-Tyr (Et)-Har-], which was designed on the basis of the above results, exhibited remarkably potent analgesic activity, being 17 times more potent than cyclo (-Tyr-Arg-) and nearly as potent as morphine on a molar basis. The structure-activity relation of cyclo(-Tyr-Arg-) is discussed in the light of these results.

  合成了30种双吡咯并哌嗪类环(-Tyr-Arg-)类似物，并评价了它们对小鼠脑室内给药后的镇痛活性。在环(-X-Arg-)系列类似物中，环[-Tyr(Et)-Arg-]显示出最强的活性。在环(-Tyr-Y-)系列类似物中，活性按Y=高精氨酸、对胍苯丙氨酸、2-氨基-4-胍基丁酸、赖氨酸、鸟氨酸、组氨酸、α,γ-二氨基丁酸和脯氨酸的顺序递减。在合成的类似物中，环-[-Tyr(Et)-Har-]基于上述结果设计，表现出极其强大的镇痛活性，比环(-Tyr-Arg-)强17倍，按摩尔计算几乎与吗啡一样有效。根据这些结果，讨论了环(-Tyr-Arg-)的构效关系。
• 一种美法仑的合成方法
  申请人：兆科（广州）肿瘤药物有限公司

  公开号：CN107935875B

  公开（公告）日：2020-07-24

  本发明公开了一种美法仑的合成方法，包括以下步骤：(a)还原反应：以具有如式I所示结构的化合物为原料，与催化剂、氢气进行还原反应制得还原产物，式I中，X代表氧或氮中的一种；R1代表氢，饱和烷基或不饱和烷基中的一种；R2和R3各自代表氢，烷羰基，氨基羰基或烷氧羰基中的一种；以烷基化试剂，与所得还原产物在缚酸剂存在下进行烷基化反应制得烷基化产物，将所得烷基化产物在酸或碱中进行水解反应，浓缩后，调pH，萃取洗涤，在干燥的盐酸的醇类或酯类溶剂中成盐，再用乙腈精制得美发仑盐酸盐。本发明各步收率高、操作简单、反应条件温和、无高毒高腐蚀试剂、得到产物纯度高及适合工业化生产的优点。
• Fluorescent amino acid derivatives
  申请人：National University Corporation Okayama University

  公开号：US07928236B2

  公开（公告）日：2011-04-19

  The subject of the present invention is to provide a fluorescent substance excitable under visible light, having higher photostability and a long fluorescence lifetime. Another subject is to provide a fluorescent substance consists of a non-natural amino acid applicable to peptide synthesis systems. Searching fluorescent substances, which are fluorescent amino acids and excitable under visible light, having the lowest possible molecular weight for a high photostability resulted in forming a condensed polycyclic aromatic compound by subjecting a compound having an acridone structure to substitution with an amino acid and further condensation with a benzene ring. Thus, the subject is achieved by the fluorescent substance consisting of amino acid-substituted benzoacridone derivative excitable under visible light.

  本发明的主题是提供一种在可见光下可激发的荧光物质，具有更高的光稳定性和长的荧光寿命。另一个主题是提供一种由非天然氨基酸构成的荧光物质，适用于肽合成系统。通过寻找荧光氨基酸并在可见光下激发，使得分子量尽可能低以获得高光稳定性的荧光物质，通过将具有吖啶酮结构的化合物经氨基酸取代和苯环进一步缩合形成紧凑的多环芳香化合物。因此，通过由氨基酸取代的苯基吖啶酮衍生物构成的在可见光下可激发的荧光物质来实现该主题。